The scientific rationale for us to consider the oral delivery of Lm-LLO-ISG15 in our orthotopic CRC model is due to the possibility that the generation of mucosal immunity may provide greater therapeutic benefit in CRC. This evidence concerns the gene ISG15 and colorectal carcinoma.